By Denny Jacob


AbbVie disclosed positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis, an autoimmune disease.

The drugmaker said its Phase 3 study showed upadacitinib in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission over a certain period of time.

Giant cell arteritis causes inflammation of medium and large arteries. It generally impacts people over the age of 50.

AbbVie also noted key secondary endpoints in the study were also met.

Upadacitinib is being studied in Phase 3 trials for alopecia areata and hidradenitis suppurativa, among others, in addition to giant cell arteritis.

Marketed under the name Rinvoq, the drug is approved in the U.S. to treat certain other inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.


Write to Denny Jacob at denny.jacob@wsj.com


(END) Dow Jones Newswires

04-18-24 0926ET